Company intelligence / Profile preview
Connect Biopharma
San Diego, California, United Statesconnectbiopharm.com ↗
- Ownership
- Public · CNTB
- Development stage
- Other
01
Overview
Lead candidate rademikibart (anti-IL-4Rα) met primary endpoint in Phase 2b for atopic dermatitis. Icanbelimod (S1P1 modulator) showed positive maintenance data in ulcerative colitis. CBP-174 (H3 receptor antagonist) completed First-in-Human studies for pruritus.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyImmunology
- Modalities
- Small moleculesMonoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Simcere
04
Financials
- Market cap
- $46.1M
- Total revenue
- $64K
- Enterprise value
- $15.2M
Beyond the preview
Go deeper on Connect Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Connect Biopharma.